Scilex Holding Co (SCLXW) stock
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex Holding Co saw revenue fall 28.5% to $31.61M over the twelve months to Jun 30, 2026. Free cash flow was $3.68M, down 81.0% from a year earlier. At the latest close the market valued the company at $17.50M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $17.50M
- P/E ratio
- –
- Price to sales
- 0.55
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $31.61M
- Net income
- -$464.56M
- EPS, diluted
- -$36.48
- Free cash flow
- $3.68M
- Book value per share
- -$44.74
- Diluted shares
- 7M
Trading
- Previous close
- $0.04
- Open
- $0.04
- Day's range
- $0.04 – $0.04
- Volume
- 2,351
- Average volume (20 days)
- 8,029
- Beta (5 years)
- 0.79
- 52-week range
- $2.01 – $27.00
- RSI (14 days)
- 15.8
- Volatility (1 year)
- 100.9%
- Relative volume
- 0.09×
- WACC
- 11.3%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | SCLXW | S&P 500 | Difference | SCLXW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -61.5% | -0.9% | −60.6 pts | ||
| 3 months | -72.7% | +2.1% | −74.8 pts | ||
| Year to date | -59.4% | +11.7% | −71.1 pts | ||
| 1 year | -83.2% | +12.4% | −95.6 pts | ||
| 3 years | -94.1% | +88.6% | −182.6 pts | -61.0% | +23.5% |
| 5 years | -93.1% | +75.9% | −169.1 pts | -41.5% | +12.0% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Scilex filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- Update
- Update
About Scilex
Biological Products, (No Diagnostic Substances)
Scilex focuses on developing and commercializing non-opioid treatments for acute and chronic pain conditions. Its commercial portfolio includes ZTlido, a prescription topical lidocaine delivery system for neuropathic pain associated with postherpetic neuralgia; ELYXYB, an oral solution indicated for the acute treatment of migraine in adults; and GLOPERBA, a liquid oral medication for preventing gout flares. The company also advances investigational candidates targeting sciatica, acute lower back pain, and fibromyalgia. Its treatments serve adult patients suffering from severe pain disorders, distributed through national and regional wholesalers and retail pharmacies following prescriptions from physicians and specialists.
Company profile, executives and historyScilex stock: common questions
What is Scilex's stock price?
SCLXW closed at $0.04 on Oct 30, 2026, down 1.53% on the day. Over the past 52 weeks it traded between $2.01 and $27.00.
What is Scilex's market cap?
Scilex was worth $17.50M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is SCLXW's P/E ratio?
Scilex lost money over fiscal 2025 (diluted EPS -$36.48), so it has no meaningful P/E ratio.
How much revenue does Scilex make?
Scilex reported revenue of $31.61M for the twelve months to Jun 30, 2026, down 28.5% from a year earlier.
Does Scilex pay a dividend?
No. Scilex has not paid a cash dividend over the last twelve months.
How has SCLXW stock performed over the past year?
Including dividends, SCLXW returned -83.2% over the past year, against +12.4% for the S&P 500.
Who are Scilex's competitors?
Companies most similar to Scilex by business, industry and size include PTHS, TNXP, LENZ, CPIX, CHRS.